St Jude Medical Inc  (STJ)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 290
 Employees 16,000
 Revenues (TTM) (Millions $) 5,956
 Net Income (TTM) (Millions $) 658
 Cash Flow (TTM) (Millions $) -965
 Capital Exp. (TTM) (Millions $) 161

St Jude Medical Inc
St.Jude Medical, Inc., together with its subsidiaries develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management (CRM), cardiac surgery (CS) and cardiology and vascular access (C/VA) therapy areas.

The Company’s principal products in each of these therapy areas are follows:


o bradycardia pacemaker systems (pacemakers),

o tachycardia implantable cardioverter defibrillator systems (ICDs), and

o electrophysiology (EP) catheters


o mechanical and tissue heart valves, and

o valve repair products


o vascular closure devices,

o angiography catheters,

o guidewires, and

o hemostasis introducers

The Company markets and sells its products through both a direct sales force and independent distributors. The principal geographic markets for the Company’s products are the United States, Europe and Japan. St. Jude also sells its products in Canada, Latin America, Australia, New Zealand and the Asia-Pacific region.

The Company has two reportable segments, the Cardiac Rhythm Management/Cardiac Surgery (CRM/CS) segment and the Daig segment, which focus on the development and manufacture of the Company’s products. The primary products produced by each segment are: CRM/CS — pacemaker and ICD systems, mechanical and tissue heart valves and other cardiac surgery products; Daig — electrophysiology catheters, vascular closure devices and other cardiology and vascular access products.

The Company’s reportable segments include end customer revenues from the sale of products they each develop and manufacture. The costs included in each of the reportable segments’ operating results include the direct costs of the products sold to end customers and operating expenses managed by each of the segments.

St. Jude purchases raw materials and other products from numerous suppliers. The Company’s manufacturing requirements comply with the rules and regulations of the FDA, which mandates extensive testing and validation of materials prior to use in the Company’s products. St. Jude maintains a one to three year supply for a small number of sole-sourced inventory items used in certain cardiac surgery products where it would be difficult to quickly establish additional or replacement vendors due to these requirements. St. Jude has been advised periodically by some suppliers that they may terminate sales of products to customers that manufacture implantable medical devices in an effort to reduce their potential product liability exposure. Some of these suppliers have modified their positions and have indicated a willingness to temporarily continue to provide product until an alternative vendor or product can be qualified, or to reconsider the supply relationship. While the Company believes that alternative sources of raw materials are available and that there is sufficient lead time in which to qualify other sources, any supply interruption could have a material adverse effect on the Company’s ability to manufacture its products.


The medical technology industry is highly competitive and is characterized by rapid product development and technological change. Within the medical technology industry, competitors range from small start-up companies to companies with significant resources. The Company’s customers consider many factors when choosing supplier partners, including product reliability, clinical outcomes, product availability, inventory consignment, price and product services provided by the manufacturer. St. Jude believes that it competes on the basis of all these factors. Market share can shift as a result of technological innovation, product recalls and product safety alerts and other business factors. As a result, the Company has a need to provide the highest quality products and services. St. Jude expects the competition to continue to increase with the use of tactics such as consigned inventory, bundled product sales and reduced pricing.

St. Jude is one of the three principal manufacturers and suppliers in the global bradycardia pacemaker market, with strong bradycardia market share in all major developed geographies. The Company’s primary competitors in this market are Medtronic, Inc. and Guidant Corporation. St. Jude is also one of three principal manufacturers and suppliers in the highly competitive global ICD market. The Company’s other two competitors, Medtronic, Inc. and Guidant Corporation, account for more than 80% of the worldwide ICD sales. These two competitors are larger than St. Jude and have invested substantial amounts in ICD research and development.

St. Jude is the world’s leading manufacturer and supplier in the mechanical heart valve market, which includes two other principal manufacturers and suppliers (Carbomedics (a Sorin Group company) and ATS Medical, Inc.) and several smaller manufacturers. The Company also competes against two principal tissue heart valve manufacturers (Edwards Lifesciences Corporation and Medtronic, Inc.) and many other smaller manufacturers.

The global cardiology and vascular access therapy area is growing and has numerous competitors. Over 70% of the Company’s sales in this area are from vascular closure devices. St. Jude currently holds the number one market position in the highly competitive vascular closure device market. Other vascular closure device competitors include Abbott Laboratories, Datascope Corp. and Vascular Solutions, Inc. We anticipate other large companies will enter this market in the coming years, which will likely increase competition.


The Company’s products are sold in more than 120 countries throughout the world.

In the United States, St. Jude sells directly to hospitals primarily through a direct sales force. In Europe, the Company has direct sales organizations selling in 15 countries. In Japan, the Company sells directly to hospitals through a direct sales force due to its acquisition of Getz Japan on April 1, 2003, and also continues to use longstanding independent distributor relationships. Throughout the rest of the world the Company uses a combination of independent distributors and direct sales forces.

Group purchasing organizations (GPOs) and independent delivery networks (IDNs) in the United States continue to consolidate purchasing decisions for some of the Company’s hospital customers. The Company has contracts in place with many of these organizations. In some circumstances, the inability of the Company to obtain a contract with a GPO or IDN could adversely affect the Company’s efforts to sell its products to that organization’s hospitals.

Payment terms worldwide are consistent with local country practices. In some developed markets and in many emerging markets, payment terms are typically longer than those in the United States. Orders are shipped as they are received and, therefore, no material backlog exists.


Customers Net Income fell by STJ's Customers Net Profit Margin grew to

-31.38 %

2.82 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
SYK        2.11% 
BSX        4% 
EW        1.31% 
MDT        4.25% 
ABT        2.16% 
• View Complete Report

I mab

I Mab declared fourth quarter of 2021 operating shortfall of $-325.034 millions

I Mab reported disastrous fourth quarter of 2021, where Sales faded by -94.16% to $13.81 millions and loss per share has widen at $-2.09, from the same quarter a year ago.

Puxin Limited

Logged a Loss by Puxin Limited in the fourth quarter of 2020 statement

In the fourth quarter of 2020 Puxin Limited lost money of $-0.03 per share compared to $-0.44 a year ago and from $0.00 per share from the previous quarter.

Compugen Ltd

Compugen Ltd declared fourth quarter of 2021 earnings season operating shortfall of $-35.074 millions

Compugen Ltd announced very strong Sales growth of 200% year on year to $6.00 millions in the fourth quarter of 2021 earnings season, but increased losses at $-0.41.

Euroseas Ltd

EPS Soared by Euroseas Ltd in the financial period ending Dec 31 2021 announcement

Euroseas Ltd delivered very strong results in the financial period ending Dec 31 2021, where Sales soared by 76.15% to $93.89 millions, while company's earnings per share soared by 944.83 % to $6.06 per share, from the same quarter a year ago.

Pacific Booker Minerals Inc

Pacific Booker Minerals Inc disclosed Sales were unchanged from the same period a year ago in the fourth quarter of 2020

Pacific Booker Minerals Inc announced operating deficit of $-0.012771518 millions, in the fourth quarter of 2020, a change from the operating loss of $-0.008108876 millions, recorded in the same quarter a year ago.


St Jude Medical Inc's Segments
ICD systems
 Segment    29.28 % of total Revenue
Pacemaker systems
 Segment    17.77 % of total Revenue
Cardiac rhythm management
 Segment    47.05 % of total Revenue
Heart valves
 Segment    10.53 % of total Revenue
Cardiac surgery
 Segment    10.53 % of total Revenue
Vascular closure devices
 Segment    13.14 % of total Revenue
Cardiology & vascular access
 Segment    13.14 % of total Revenue
Atrial fibrillation
 Segment    20.24 % of total Revenue
Neuromodulation products
 Segment    9.04 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
St Jude Medical Inc does not provide revenue guidance.

Earnings Outlook
Pacific Booker Minerals Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States 47.26 %
Japan 9.36 %
Other International 43.38 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

SFLL's Profile

Stock Price

SFLL's Financials

Business Description


Charts & Quotes

SFLL's News


SFLL's Competitors

Customers & Markets

Economic Indicators

SFLL's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071